Terms: = Skin cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
37 results:
1. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
[TBL] [Abstract] [Full Text] [Related]
2. Mi-2β promotes immune evasion in melanoma by activating ezh2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract] [Full Text] [Related]
3. Combined Inhibition of ezh2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract] [Full Text] [Related]
4. 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Hosokawa M; Tetsumoto S; Yasui M; Kono Y; Ogawara KI
Biochem Biophys Res Commun; 2023 Oct; 677():26-30. PubMed ID: 37542772
[TBL] [Abstract] [Full Text] [Related]
5. Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus.
Khattri M; Amako Y; Gibbs JR; Collura JL; Arora R; Harold A; Li MY; Harms PW; Ezhkova E; Shuda M
Tumour Virus Res; 2023 Dec; 16():200264. PubMed ID: 37244352
[TBL] [Abstract] [Full Text] [Related]
6. SHR2554, an ezh2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
Song Y; Liu Y; Li ZM; Li L; Su H; Jin Z; Zuo X; Wu J; Zhou H; Li K; He C; Zhou J; Qi J; Hao S; Cai Z; Li Y; Wang W; Zhang X; Zou J; Zhu J
Lancet Haematol; 2022 Jul; 9(7):e493-e503. PubMed ID: 35772429
[TBL] [Abstract] [Full Text] [Related]
7. Merkel Cell Carcinoma Sensitivity to ezh2 Inhibition Is Mediated by SIX1 Derepression.
Gartin AK; Frost TC; Cushman CH; Leeper BA; Gokhale PC; DeCaprio JA
J Invest Dermatol; 2022 Oct; 142(10):2783-2792.e15. PubMed ID: 35331717
[TBL] [Abstract] [Full Text] [Related]
8. Dual Targeting with ezh2 Inhibitor and STING Agonist to Treat Melanoma.
Emran AA; Fisher DE
J Invest Dermatol; 2022 Apr; 142(4):1004-1006. PubMed ID: 35131084
[TBL] [Abstract] [Full Text] [Related]
9. Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.
Fane ME; Chhabra Y; Spoerri L; Simmons JL; Ludwig R; Bonvin E; Goding CR; Sturm RA; Boyle GM; Haass NK; Piper M; Smith AG
J Invest Dermatol; 2022 Jul; 142(7):1845-1857. PubMed ID: 34958806
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and predictive value of ezh2 expression and the tumor immune microenvironment in Merkel cell carcinoma.
Acikalin A; Bagir E; Paydas S
Pol J Pathol; 2021; 72(2):140-147. PubMed ID: 34706521
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
[TBL] [Abstract] [Full Text] [Related]
12. AP-2α-Mediated Activation of E2F and ezh2 Drives Melanoma Metastasis.
White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
[TBL] [Abstract] [Full Text] [Related]
13. lncRNA HCP5 acts as a ceRNA to regulate ezh2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.
Zou S; Gao Y; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195851
[TBL] [Abstract] [Full Text] [Related]
14. PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Sci Rep; 2021 May; 11(1):11023. PubMed ID: 34040017
[TBL] [Abstract] [Full Text] [Related]
15. Long Noncoding RNA
Pistoni M; Rossi T; Donati B; Torricelli F; Polano M; Ciarrocchi A
Mol Cancer Res; 2021 May; 19(5):799-811. PubMed ID: 33547232
[TBL] [Abstract] [Full Text] [Related]
16. ezh2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract] [Full Text] [Related]
17. Tazemetostat: First Approval.
Hoy SM
Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
[TBL] [Abstract] [Full Text] [Related]
18. Verification of ezh2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract] [Full Text] [Related]
19. Targeting DNA Methylation and ezh2 Activity to Overcome Melanoma Resistance to Immunotherapy.
Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P
Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334
[TBL] [Abstract] [Full Text] [Related]
20. Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin.
Li N; Liu Y; Pang H; Lee D; Zhou Y; Xiao Z
Med Sci Monit; 2019 Mar; 25():1590-1599. PubMed ID: 30821276
[TBL] [Abstract] [Full Text] [Related]
[Next]
